This single-center, double-blind, placebo-controlled study will recruit in total 39
participants with either Mild Cognitive Impairment due to Alzheimer's disease (MCI) or Mild
Alzheimer's disease dementia (mild AD). There will be 3 Dose levels. An initial cohort of 13
subjects will be randomized to a Dose level 1 (0.1 mg/kg vs. placebo) lasting 8 weeks. An
additional 13 subjects will be recruited and randomized into Dose level 2 (0.25 mg/kg vs.
placebo) for 8 weeks and 13 subjects for the last Dose level 3 (0.5 mg/kg vs. placebo) for 8
weeks. The primary objective will be to assess safety and tolerability of CpG 1018.